THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS

• Egile Nagusiak: A. V. Rudakova (Egilea), I. V. Babachenko (Egilea), V. B. Rovnyi (Egilea), A. N. Uskov (Egilea), Yu. V. Lobzin (Egilea)
• Formatua: Liburua
• Argitaratua: "Paediatrician" Publishers LLC, 2012-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Respiratory syncytial virus plays a significant role in etiology of respiratory infections in infants, and preterm children have muchhigher risk of severe course of the disease, than common population of children at the age less than 2 years old. Palivizumab is usedefficiently to prevent this infect...